To discuss the evidence base, clarity, and application of the first EHA guidelines for CLL and Richter transformation, and to propose considerations for future updates.
Approach:
Guideline context: The commentary reviews recommendations spanning CLL diagnosis, surveillance, supportive care, and treatment, noting that they draw on prospective trials and real-world registries.
Treatment recommendations: It examines the evidence supporting first-line choices, including fixed-duration versus continuous targeted therapy and selection among BTK inhibitors.
Clinical benefit scoring and personalization: It discusses use of the ESMO Magnitude of Clinical Benefit Scale for hematologic malignancies (MCBS:H) and the guidelines’ approach to individual treatment selection.
Key Findings:
The authors state that evidence gaps remain, particularly because mature randomized head-to-head comparisons of targeted regimens are limited.
The commentary argues that preferring time-limited therapy for patients without TP53 aberrations is not supported by studies demonstrating superiority over continuous treatment.
It cautions that avoiding continuous therapy in patients with mutated IGHV may be overly categorical; continuous treatment remains effective, and convenience may matter, particularly for older patients.
The preference for acalabrutinib or zanubrutinib over ibrutinib in continuous first-line treatment is described as an extrapolation from relapsed/refractory studies rather than Level IA evidence.
MCBS:H scores depend on trial and population characteristics, comparator choice, follow-up, endpoints, and subsequent therapies; the authors caution against treating a higher score as inherently superior.
The guidelines emphasize TP53 and IGHV status and include selected comorbidities in treatment selection, but the commentary identifies limited guidance on frailty and the needs of older patients.
Interpretation:
The commentary calls for recommendations to be clearly linked to their evidence levels and for MCBS:H scores and trial findings to be interpreted in context. It also argues that treatment selection should account more explicitly for frailty, comorbidities, and the populations represented in pivotal trials.
Limitations:
The supplied article context ends mid-sentence, so the commentary’s remaining discussion and any final conclusions are unavailable.
The commentary notes that evidence is heterogeneous and that mature randomized head-to-head studies of targeted regimens are limited.
The authors state that formal MCBS:H assessment is pending for some pivotal trials and that not all scores have been validated.
by Alessandra Tedeschi, Raul Cordoba, Alessandra Ferrajoli, George Follows, Anna Maria Frustaci, Anne Sophie Michallet, Talha Munir, Susan O'Brien, John F. Seymour, Tait Shanafelt, Clemens Martin Wendtner, Pier Luigi Zinzani, Stephan Stilgenbauer
Harold Burstein, MD, PhD, and Laura S. Dominici, MD, FACS, discuss highlights from the SENOMAC trial which sheds light on whether some patients with early breast cancer and limited lymph node involvement can safely avoid additional axillary surgery.
